==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

1820 details
Primary information
ThPP IDTh1211
Therapeutic Peptide/Protein NameIxekizumab
SequenceNA view full sequnce in fasta
Functional ClassificationIc
Molecular Weight1,46,158
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeThe mean (geometric CV%) half-life was 13 days
DescriptionIxekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) with neutralizing activity against IL-17A. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule.
Indication/DiseaseFor the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
PharmacodynamicsNo formal pharmacodynamic studies have been conducted with TALTZ.
Mechanism of ActionIxekizumab is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of proinflammatory cytokines and chemokines.
ToxicityNA
MetabolismNA
AbsorptionIxekizumab reached peak mean (±SD) serum concentrations (Cmax) of 16.2 ±6.6 mcg/mL by approximately 4 days post dose.
Volume of Distributionvolume of distribution at steady-state was 7.11 L
ClearanceThe mean systemic clearance was 0.39 L/day
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Information of corresponding available drug in the market
Brand NameTaltz
CompanyEli lilly
Brand DiscriptionTALTZ injection is a sterile, preservative free, clear and colorless to slightly yellow solution, for subcutaneous use available as 80 mg of ixekizumab in a 1 mL single-dose prefilled autoinjector or a single-dose prefilled syringe. The prefilled autoinjector and prefilled syringe each contain a 1 mL glass syringe with a fixed 27 gauge ½ inch needle. The TALTZ 80 mg prefilled autoinjector and prefilled syringe are manufactured to deliver 80 mg of ixekizumab.
Prescribed forTaltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Chemical NameNA
Formulation80 mg of ixekizumab in a 1 mL single-dose prefilled autoinjector or a single-dose prefilled syringe
Physcial AppearnceSterile, preservative free, clear and colorless to slightly yellow solution
Route of AdministrationSubcutaneous
Recommended DosageTALTZ is administered by subcutaneous injection. The recommended dose is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.
ContraindicationTALTZ is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients
Side EffectsInfections; Hypersensitivity Reactions; Inflammatory Bowel Disease
Useful Linkhttp://www.rxlist.com/taltz-drug.htm; http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003943/WC500205806.pdf
PubMed ID27313431, 26651519, 25484055, 24284914, 23254906, 28042711, 28026823, 27836567, 27826996
3-D StructureN.A.